Chronic Traumatic Encephalopathy (CTE) – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Chronic Traumatic Encephalopathy (CTE) – Pipeline Review, H2 2018’, provides an overview of the Chronic Traumatic Encephalopathy (CTE) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Traumatic Encephalopathy (CTE), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Traumatic Encephalopathy (CTE) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chronic Traumatic Encephalopathy (CTE)

– The report reviews pipeline therapeutics for Chronic Traumatic Encephalopathy (CTE) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chronic Traumatic Encephalopathy (CTE) therapeutics and enlists all their major and minor projects

– The report assesses Chronic Traumatic Encephalopathy (CTE) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chronic Traumatic Encephalopathy (CTE)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chronic Traumatic Encephalopathy (CTE)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chronic Traumatic Encephalopathy (CTE) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Eustralis Pharmaceuticals Ltd

Prothena Corp Plc

Tetra Discovery Partners LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chronic Traumatic Encephalopathy (CTE) Overview

Chronic Traumatic Encephalopathy (CTE) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chronic Traumatic Encephalopathy (CTE) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Traumatic Encephalopathy (CTE) Companies Involved in Therapeutics Development

Eustralis Pharmaceuticals Ltd

Prothena Corp Plc

Tetra Discovery Partners LLC

Chronic Traumatic Encephalopathy (CTE) Drug Profiles

cannabidiol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EUC-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Tau for Neurology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

N-acetyl cysteine amide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PU-AD Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TDP-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Tau for Alzheimer's Disease and Chronic Traumatic Encephalopathy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Traumatic Encephalopathy (CTE) Product Development Milestones

Featured News & Press Releases

May 22, 2018: Dateline NBC Segment Features Medical Marijuana Portfolio Company Kannalife Sciences

May 18, 2018: Kannalife Sciences to be Featured in Dateline NBC Segment Covering Companys Research on CBD-Like Molecules as Treatments for HE, CTE

Jan 29, 2018: United Neuroscience Announces Development Plans for Vaccine to Prevent CTE

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chronic Traumatic Encephalopathy (CTE), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Chronic Traumatic Encephalopathy (CTE) Pipeline by Eustralis Pharmaceuticals Ltd, H2 2018

Chronic Traumatic Encephalopathy (CTE) Pipeline by Prothena Corp Plc, H2 2018

Chronic Traumatic Encephalopathy (CTE) Pipeline by Tetra Discovery Partners LLC, H2 2018

List of Figures

List of Figures

Number of Products under Development for Chronic Traumatic Encephalopathy (CTE), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports